Inhalation of MSC-EVs is a noninvasive strategy for ameliorating acute lung injury
Authors:
Open Access
- 17 March 2022
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 345, 214-230
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational designActa Pharmaceutica Sinica B, 2021
- Investigation of the MSC Paracrine Effects on Alveolar–Capillary Barrier Integrity in the In Vitro Models of ARDS2021
- MSC-derived exosomes protect against oxidative stress-induced skin injury via adaptive regulation of the NRF2 defense systemBiomaterials, 2020
- Acute respiratory distress syndromeNature Reviews Disease Primers, 2019
- Sirtuin 6 mitigated LPS‐induced human umbilical vein endothelial cells inflammatory responses through modulating nuclear factor erythroid 2‐related factor 2Journal of Cellular Biochemistry, 2019
- Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelinesJournal of Extracellular Vesicles, 2018
- Selenium Pretreatment Alleviated LPS-Induced Immunological Stress Via Upregulation of Several Selenoprotein Encoding Genes in Murine RAW264.7 CellsBiological Trace Element Research, 2018
- Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trialThe Lancet Respiratory Medicine, 2015
- A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-κB and hypoxia-inducible factor-1αExperimental & Molecular Medicine, 2007
- Nrf2 Defends the Lung from Oxidative StressAntioxidants & Redox Signaling, 2006